1401PD - Fluctuating cancer screening uptake in France: results of the 5th EDIFICE survey

Date 09 September 2017
Event ESMO 2017 Congress
Session Public health policy and health economics
Topics Cancer in Adolescents
Cancer Aetiology, Epidemiology, Prevention
Presenter Jérôme Viguier
Citation Annals of Oncology (2017) 28 (suppl_5): v502-v506. 10.1093/annonc/mdx383
Authors J. Viguier1, S. Couraud2, L. Greillier3, J. Blay4, C. Touboul5, C. Lhomel6, A. Cortot7, J. Morere8, F. Eisinger9
  • 1Public Health And Care, The French National Cancer Institute (INCa), 92513 - Boulogne-Billancourt Cedex/FR
  • 2Respiratory Diseases And Thoracic Oncology, Centre Hospitalier Lyon Sud, 69495 - Pierre Bénite/FR
  • 3Multidisciplinary Oncology And Therapeutic Innovations, Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, 13009 - Marseille/FR
  • 4Medical Oncology, Centre Leon Berard, 69008 - Lyon/FR
  • 5Statistics, Kantarhealth, 75014 - Paris/FR
  • 6Medical, Roche - France, 9265000 - Boulogne-Billancourt/FR
  • 7Pneumology-oncology, Hospital Albert Calmette, 59000 - Lille/FR
  • 8Medical Oncology, Hopital Paul Brousse, 94804 - Villejuif/FR
  • 9Aix Marseille Univ, Inserm, Sesstim, Institute Paoli Calmettes, 1300674 - Marseille/FR

Abstract

Background

The EDIFICE nationwide surveys assess attitudes to cancer screening in France. All 5 self-reported surveys (2005, 2008, 2011, 2014 and 2016) focused on breast (BC), colorectal (CRC), prostate cancer (PC) screening; the 4th and 5th editions also included cervical (CC) and lung cancer (LC) screening.

Methods

The 5th survey recruited a representative sample of 1299 subjects (men [M], women [F]; age, 50-74 y; no history of cancer) and focused on target populations of the national screening programs for BC and CRC (50-74 y), and on specific subpopulations for PC (M, 50-75 y), CC (F, 50-65 y) and LC (M and F, 55-74 y) screening. Participants were questioned about uptake of at least 1 lifetime screening test and compliance to recommended intervals. Data analysis encompassed nationwide screening programs, opportunistic screening, and vulnerability (assessed by the EPICES score).

Results

Rates for at least 1 lifetime BC screening test (screening rate) were 93%/94%/95%/97%/97% in 2005/2008/2011/2014/2016, respectively. In line with recommendations, 75%/83%/83%/81%/75% women reported having had a mammogram in the past 2 years (compliance), with a significant drop in 2016 vs 2014 (P=0.02). Vulnerability had a negative impact on compliance in 2016, though not previously. For CRC, screening rates were 25%/38%/59%/60%/64%. Compliance (FOBT or FIT in the past 2 years) increased steadily from 7% (2005) to 33% (2014), and rose significantly to 38% in 2016 (P=0.02). The rise was mainly observed in the 50-54 y age group, among men, and in non-vulnerable subjects. In 2016, a significant drop in overall CC screening uptake was observed (99% in 2014 vs 94% in 2016, P

Conclusions

In 2016, compliance to national programs was seen to be high for BC screening (despite a decline), and on the rise for CRC, possibly due to the use since 2015 of the new FIT test. Although a national program is due to be implemented in France, uptake of CC screening is on the decline.

Clinical trial identification

Legal entity responsible for the study

Kantar Health

Funding

Roche France

Disclosure

S. Couraud, L. Greillier, J-Y. Blay, A. Cortot, J-F. Morere, F. Eisinger: Received honorarium fees from Roche/Edifice surveys were funded by Roche S.A. C. Lhomel: Employee of Roche. All other authors have declared no conflicts of interest.